Intellia Therapeutics Inc 's Cash & cash equivalent grew by 8.3 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Intellia Therapeutics Inc 's Quick Ratio to 5.9, Quick Ratio remained below Intellia Therapeutics Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry only one company has achieved higher Quick Ratio in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 606 to 759.

Explain Quick Ratio?
How much Cash & cash equivalents NTLA�s has?
What are NTLA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NTLA/financial-strength

https://api.csimarket.com/api/v1/companies/NTLA/fundamentals

https://api.csimarket.com/api/v1/companies/NTLA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

NTLA Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-14.32 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-7.23 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	5.9	Subscribe	Subscribe	Subscribe	Subscribe
NTLA's Total Ranking	# 759	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	1.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	8.3 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 2
Healthcare Sector	# 284
Overall Market	# 759

Quick Ratio Statistics
High	Average	Low
13.91	8.01	4.33
(Jun 30 2016)		(Dec 31 2025)

Financial Statements
Intellia Therapeutics Inc 's Current Liabilities	$ 80 Millions	Visit NTLA's Balance sheet
Intellia Therapeutics Inc 's Cash & cash equivalent	$ 474 Millions	Visit NTLA's Balance sheet
Source of NTLA's Sales		Visit NTLA's Sales by Geography

Cumulative Intellia Therapeutics Inc 's Quick Ratio

NTLA's Quick Ratio for the trailling 12 Months

NTLA Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-17.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-16.29 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	5.11	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3855	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-3.8 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-2.08 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to NTLA Financial Strength Comparisons >> Go to Compare NTLA Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Intellia Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Intellia Therapeutics Inc 's Quick Ratio to 5.11, above NTLA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Intellia Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3677 to 3855.

Explain Quick Ratio?
How much Cash & cash equivalents NTLA�s has?
What are NTLA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 886
Within the Market	# 3855

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.73	4.05	1.08
(Sep 30 2018)		(Sep 30 2022)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Achieve Life Sciences Inc	14.81	$ 201.518 Millions	$ 13.610 Millions
Celldex Therapeutics inc	10.75	$ 650.319 Millions	$ 60.517 Millions
Intellia Therapeutics Inc	5.90	$ 474.110 Millions	$ 80.306 Millions
Lantheus Holdings Inc	1.98	$ 683.610 Millions	$ 345.967 Millions
Alpha Teknova Inc	1.86	$ 16.560 Millions	$ 8.926 Millions

Date modified: 2026-11-09T18:44:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.